Navigating the Future of Cutaneous Squamous Cell Carcinoma (cSCC): An Expert Discussion on Modern Immunotherapy - Episode 11

The Evolving Role of Adjuvant Immunotherapy

November 10, 2025

Soo Park, MD, Vishal A. Patel, MD, FAAD, FACMS, Neil D. Gross, MD, FACS, Mehran Yusuf, MD

Panelists discuss ongoing clinical trials, including adjuvant immunotherapy studies, and identify which patients are most likely to benefit from these strategies.

EP. 1: Approach to Evaluating Suspected cSCC

EP. 2: Assessing Risk in cSCC: Key Clinical and Pathologic Markers

EP. 3: Dermatology’s Role in Diagnosing and Managing cSCC

EP. 4: Balancing In-Clinic Treatment and Referral in cSCC

EP. 5: Applying Guideline-Based Care Pathways in cSCC

EP. 6: Recognizing High-Risk cSCC Patients for Early Biopsy

EP. 7: Defining Primary Treatment Options in cSCC

EP. 8: Identifying Surgical Candidates in cSCC

EP. 9: Role of Radiotherapy in Managing cSCC

EP. 10: Integrating Systemic Therapy Into cSCC Management

Now Viewing

EP. 11: The Evolving Role of Adjuvant Immunotherapy

EP. 12: Selecting Candidates for Adjuvant Immunotherapy in cSCC

EP. 13: Clinical Trial Design and Outcomes in Adjuvant Immunotherapy for cSCC

EP. 14: Long-Term Follow-Up and Surveillance After Adjuvant Therapy

EP. 15: Optimizing Multidisciplinary Collaboration in cSCC Care

Panelists examine clinical trials exploring immunotherapy in high-risk postoperative cutaneous squamous cell carcinoma (cSCC), including studies evaluating checkpoint inhibition in the adjuvant setting. Early data suggest improved recurrence-free survival in patients with deep invasion, nodal disease, or perineural spread.

They discuss how trial results are beginning to shift practice patterns, with adjuvant immunotherapy emerging as an option for select high-risk patients after curative-intent surgery and radiation. Biomarker research may further refine candidate selection.

The discussion underscores that these advances exemplify precision oncology in cSCC—aligning therapeutic intensity with risk and biology to prevent recurrence and improve long-term outcomes.